Onconetix, Inc. (ONCO)
0.9962
+0.26
(+34.80%)
USD |
NASDAQ |
Sep 04, 16:00
0.8579
-0.14
(-13.88%)
After-Hours: 16:30
Onconetix Research and Development Expense (TTM) : 0.0753M for June 30, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.0753M |
| March 31, 2026 | -0.0398M |
| December 31, 2025 | -0.0661M |
| September 30, 2025 | |
| June 30, 2025 | |
| March 31, 2025 | |
| December 31, 2024 | |
| September 30, 2024 | |
| June 30, 2024 | |
| March 31, 2024 |
| Date | Value |
|---|---|
| December 31, 2023 | |
| September 30, 2023 | 3.354M |
| June 30, 2023 | 4.310M |
| March 31, 2023 | 4.757M |
| December 31, 2022 | 4.130M |
| September 30, 2022 | 3.361M |
| June 30, 2022 | 2.456M |
| March 31, 2022 | 1.251M |
| December 31, 2021 | 0.8971M |
| September 30, 2021 | 0.5627M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Aprea Therapeutics, Inc. | 6.721M |
| ACADIA Pharmaceuticals, Inc. | 331.01M |
| Alnylam Pharmaceuticals, Inc. | 1.509B |
| Anika Therapeutics, Inc. | 27.45M |
| Savara, Inc. | 86.84M |